OncoMatch/Clinical Trials/NCT06305247
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Is NCT06305247 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including IPN01194 and IPN01194 for melanoma.
Treatment: IPN01194 · IPN01194 — The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Head and Neck Squamous Cell Carcinoma
Pancreatic Cancer
Colorectal Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-cancer therapy
Concurrent treatment with any other anti-cancer therapy (including radiotherapy or investigational agents).
Cannot have received: investigational agent
Current enrolment or past participation in any other clinical trial involving an investigational study treatment within the last 28 days.
Lab requirements
Blood counts
Non-adequate bone marrow function [excluded]
Kidney function
Non-adequate renal function [excluded]
Liver function
Non-adequate hepatic function [excluded]
Cardiac function
Non-adequate cardiac function [excluded]
Non-adequate cardiac function; Non-adequate bone marrow function; Non-adequate renal function; Non-adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Angeles Clinic and Research Institute - California · Los Angeles, California
- UC San Diego Health System - La Jolla · San Diego, California
- Yale Cancer Center - New Heaven · New Haven, Connecticut
- Sarah Cannon Research Institute (SCRI) - Nashville · Nashville, Tennessee
- Virginia Cancer Specialist · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify